Saturday 17 October 2026
Export CMND’s income statement to Excel — free account
Clearmind Medicine Inc.
CMND Healthcare Biotechnology
In the quarter to July 2026, EPS grew 99.4%, free cash flow fell 77.9% and total debt rose 10,410.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.26
0.16
−2.49%
Follow CMND
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
| (106.98%) | (114.61%) | (119.72%) | (179.38%) |
+8 more TTM periods Free account |
|
| (71.81%) | (80.22%) | (74.91%) | (57.83%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(58.72%) | (69.73%) | (81.82%) | (364.82%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.47) | (20.61) | (47.80) | (372.80) | |
Free Cash Flow |
(7.07) | (6.22) | (5.55) | (4.73) | |
| Other line items | |||||
Cash ROIC |
(23.10%) | (24.77%) | (29.88%) | (55.45%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.02 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (318.71) | (261.91) | — | |
Operating CF/Net income |
0.94 | 0.79 | 0.84 | 1.23 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.47) | (20.61) | (47.80) | (372.80) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates